EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bcl-2 pathway inhibition in solid tumors: a review of clinical trials

Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis-Alexios Koumprentziotis, Konstantinos Karampinos, Konstantinos Drougkas, Ioannis Karavolias, Ioannis Trontzas, Elias A Kotteas

Clinical and Translational Oncology · 2023

DOI: 10.1007/s12094-022-03070-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Oncology, 2023. Verfasst von Ioanna Ploumaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms. Die Arbeit wurde bisher 96-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Athens.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to their key role in the pathogenesis of cancer through the regulation of apoptosis, the B-cell leukemia/lymphoma-2 (BCL-2) family proteins have been an attractive target for cancer therapy for the past decades. Throughout the years, many Bcl-2 family inhibitors have been developed, with Venetoclax being now successfully used in treating hematological malignancies. Although their effectiveness in the treatment of solid tumors is yet to be established, some preclinical evidence indicates their possible clinical application. This review aims to summarize current data from completed clinical trials that used Bcl-2 protein family inhibitors as monotherapy or in combination with other agents for the treatment of solid malignancies. We managed to include clinical trials of various phases which analyze the pharmacokinetics and pharmacodynamics of the drugs, as well as the effectiveness and adverse effects. Active and recruiting clinical trials are also briefly presented and future prospects and challenges are discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Lymphocytic, Chronic, B-CellHematologic NeoplasmsHumansProto-Oncogene Proteins c-bcl-2ApoptosisBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

Bcl-2 inhibitorsChemotherapyNavitoclaxOblimersenSolid tumorsVenetoclax

Substanzen

Proto-Oncogene Proteins c-bcl-2Antineoplastic AgentsBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
  • Oncology Unit, 3rd Department of Medicine, 'Sotiria' General Hospital, National and Kapodistrian University of Athens, Athens, Greece. giannhskmpr@gmail.com.

Förderung

  • University of Athens

Zitieren

APA

Ploumaki, I., Triantafyllou, E., Koumprentziotis, I. A., Karampinos, K., Drougkas, K., Karavolias, I., Trontzas, I., & Kotteas, E. A. (2023). Bcl-2 pathway inhibition in solid tumors: a review of clinical trials. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-022-03070-9

Vancouver

Ploumaki I, Triantafyllou E, Koumprentziotis IA, Karampinos K, Drougkas K, Karavolias I, et al. Bcl-2 pathway inhibition in solid tumors: a review of clinical trials. Clinical and Translational Oncology. 2023. doi:10.1007/s12094-022-03070-9

BibTeX
@article{Ploumaki2023,
  author = {Ploumaki, Ioanna and Triantafyllou, Efthymios and Koumprentziotis, Ioannis-Alexios and Karampinos, Konstantinos and Drougkas, Konstantinos and Karavolias, Ioannis and Trontzas, Ioannis and Kotteas, Elias A},
  title = {Bcl-2 pathway inhibition in solid tumors: a review of clinical trials},
  journal = {Clinical and Translational Oncology},
  year = {2023},
  doi = {10.1007/s12094-022-03070-9}
}
Kostenlos starten →